Chan Beals, M.D., Ph.D.
Senior Vice President, Translational Medicine
Dr. Beals is senior vice president of translational medicine at Autobahn Therapeutics
Prior to Autobahn, Dr. Beals was chief medical officer at Abide Therapeutics from 2016 until its sale to H. Lundbeck A/S in 2019. Prior to Abide, Dr. Beals was an entrepreneur in residence with Merck Research Laboratories Ventures, a vehicle by which Merck interacts with nascent biotechnology companies. In that role, Dr. Beals was involved with all facets of search and evaluation, deal terms, building internal consensus for investments and monitoring their progress. Prior to his role at Merck Research Laboratory Ventures, Dr. Beals was vice president and head of clinical pharmacology and experimental therapeutics at Merck & Co, where he was responsible for overseeing preclinical and clinical development of new therapeutics. During that time, Dr. Beals led the introduction of 30 molecules into early clinical development, of which 11 molecules entered late stage clinical development. Dr. Beals earned his M.D. and Ph.D. in biochemistry from the University of Washington School of Medicine and his B.S. in chemistry from the Massachusetts Institute of Technology. He completed a residency in pediatrics and fellowship in pediatric rheumatology at the University of California, San Francisco.